胰岛素联合利拉鲁肽治疗肥胖2型糖尿病的临床疗效

Clinical Efficacy of Insulin Therapy in Obese Type 2 Diabetic Patients with Liraglutide

目的评价胰岛素+利拉鲁肽对肥胖2型糖尿病进行治疗的临床效果。方法对2018年4月至2019年8月我院收治的64例肥胖2型糖尿病患者以随机方法分为观察组与对照组,均32例。分别对两组患者通过胰岛素联合利拉鲁肽和单纯胰岛素治疗,对比两组治疗效果。结果观察组[90.63%(29/32)]的血糖控制有效率高于对照组[65.63%(21/32)],有统计学差异(P<0.05);观察组[6.25%(2/32)]的不良反应发生率无异于对照组[6.25%(2/32)],无统计学差异(P>0.05);观察组的空腹血糖值、餐后2 h血糖值、糖化血红蛋白水平、日胰岛素使用量、体质量优于对照组,有统计学差异(P<0.05)。结论通过胰岛素联合利拉鲁肽可在安全的前提下治疗肥胖2型糖尿病患者,促进其身体指标的改进,值得推荐。

Objective To evaluate the clinical effect of insulin+liraglutide in the treatment of obese type 2 diabetes.Methods A total of 64 obese type 2 diabetes patients admitted to our hospital from April 2018 to August 2019 were randomly divided into observation group and control group,with 32 cases in each group.The two groups of patients were treated with insulin combined with liraglutide and insulin alone,to compare the treatment effects of the two groups.Results The effective rate of blood glucose control in the observation group[90.63%(29/32)]was higher than that of the control group[65.63%(21/32)],which was statistically different(P<0.05);the observation group[6.25%(2/32)]the incidence of adverse reactions was the same as that of the control group[6.25%(2/32)],and there was no statistical difference(P>0.05);the observation group's fasting blood glucose level,2 hours postprandial blood glucose level,glycosylated hemoglobin level,daily insulin usage and body weight were better than those of the control group,with statistical differences(P<0.05).Conclusion The combination of insulin and liraglutide can treat obese type 2 diabetic patients under the premise of safety and promote the improvement of their physical indicators.It is worth recommending.